Harshman et al. demonstrated the higher expression of CD44, a glycoprotein implicated in invasiveness, cancer cell trafficking, resistance to apoptosis, and therapy, in circulating EVs of 32 MM patients at diagnosis compared to healthy individuals [52]. The gene discussed is CD44; the disease is Miyoshi myopathy.